$Evoke Pharma (EVOK.US)$Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025 Benzinga· 2 mins ago FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to...
$Evoke Pharma (EVOK.US)$ Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends Thursday, 19th December at 8:30 am FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Phar...
1
9
Report
Trytosaveabit
:
What do think the ramifications of this could be? Good and bad? When you got time Brother!
Trytosaveabit
Jaguar8
OP
:
That’s what I thought! But doesn’t it actually give a pathway for EVOK to bring there’s in as a potential replacement? Or am I reading that wrong? Hehehe
Trytosaveabit
Jaguar8
OP
:
Oh my bad! So you’re working part time and I’m at about 1/4 speed today! So between the 2 of us we still are not considered full time! Hehehe
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
$Evoke Pharma (EVOK.US)$ Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® Tuesday, 3rd December at 8:30 am SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent appli...
$Evoke Pharma (EVOK.US)$ Evoke Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Laurence W. Lytton(9.99%)
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Evoke Pharma Stock Forum
anyone got any news?
📊⚡️📊
Benzinga· 2 mins ago
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to...
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Thursday, 19th December at 8:30 am
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Phar...
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Tuesday, 3rd December at 8:30 am
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent appli...
Evoke Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Laurence W. Lytton(9.99%)
will it ever rise?
No comment yet